Eradication of colorectal xenografts by combined radioimmunotherapy and combretastatin A-4 3-O-phosphate

Cancer Research

Volumn 61, Issue 12, 2001, Pages 4716-4722

  Pedley, R Barbara ^a   Hill, Sally A ^b   Boxer, Geoffrey M ^a   Flynn, Aiden A ^a   Boden, Robert ^a   Watson, Rebecca ^a   Dearling, Jason ^a   Chaplin, David J ^b   Begent, Richard H J ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b MOUNT VERNON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARCINOEMBRYONIC ANTIGEN; COMBRETASTATIN A4 3 O PHOSPHATE; IMMUNOGLOBULIN G; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER IMMUNOTHERAPY; COLORECTAL CANCER; HUMAN; MULTIMODALITY CANCER THERAPY; NECROSIS; NEOVASCULARIZATION (PATHOLOGY); NUDE MOUSE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; SOLID TUMOR; TUMOR BLOOD FLOW; TUMOR LOCALIZATION; XENOGRAFT;

ADENOCARCINOMA; ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CELL DIVISION; COLONIC NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; IMMUNOTOXINS; IODINE RADIOISOTOPES; MICE; MICE, NUDE; RADIOIMMUNOTHERAPY; STILBENES; TISSUE DISTRIBUTION; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0035874889     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Pharmacokinetics of monoclonal antibodies: Implications for their use in cancer therapy
2. Radiolabeled antibody therapy of B-cell lymphoma with autologous bone marrow support
3. 2 antibodies
4. Delivery of novel therapeutic agents in tumours: Physiological barriers and strategies
5. The next frontier of molecular medicine: Delivery of therapeutics
6. Effectiveness of radiolabeled antibodies for radioimmunotherapy in a colorectal xenograft model: A comparative study using the linear-quadratic formulation
7. A novel technique, using radioluminography, for the measurement of uniformity of radiolabeled antibody distribution on a colorectal cancer xenograft model
8. Structure of solid tumors and their vasculature: Implications for therapy with monoclonal antibodies
9. Ablation of colorectal xenografts with combined radioimmunotherapy and tumour blood flow modifying agents
10. Combretastatin A4, an agent that displays potent and selective toxicity toward tumor vasculature
11. Colchicine in the experimental chemotherapy of cancer
12. Combretastatin A-4 phosphate as a tumor vascular-targeting agent: Early effects in tumors and normal tissues
13. In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug
14. Combination chemotherapy with combretastatin A-4 phosphate and 5-fluorouracil in an experimental murine colon adenocarcinoma
15. Enhancement of antibody-directed enzyme prodrug therapy in colorectal xenografts by an antivascular agent
16. Targeting tumour vasculature: The development of combretastatin A4
17. Anti-vascular approaches to solid tumour therapy: Evaluation of combretastatin A4 phosphate
18. Changes in human tumour perfusion after DMXAA treatment, monitored by Gd-DTPA-enhanced MRI
19. Relationship between tumour size and uptake of radiolabelled anti-CEA antibody in a colon tumour xenograft
20. Antibody-directed enzyme prodrug therapy: Pharmacokinetics and plasma levels of prodrug and drug in a Phase I clinical trial
21. Control of differentiation in human colorectal carcinoma cell lines: Epithelial-mesenchymal interactions
22. Hypoxia and vascular endothelial growth factor expression in human squamous cell carcinomas using pimonidazole as a hypoxic marker
23. A comparison of image registration techniques for the correlation of radiolabelled antibody distribution with tumour morphology
24. A mathematical evaluation of tumour growth curves in rapid, intermediate, and slow growing rat hepatoma
25. A computer program for comparing K samples with right censored data
26. Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature
27. Combined effects of angiostatin and ionizing radiation in antitumor therapy
28. Synergy between an antiangiogenic integrin α(v) antagonist and an antibody-cytokine fusion protein eradicates spontaneous tumor metastases
29. Magnetic resonance imaging and spectroscopy of combretastatin A4 prodrug-induced disruption of tumour perfusion and energy status
30. Induction of apoptosis in proliferating human endothelial cells by the tumor-specific antiangiogenesis agent combretastatin A-4
31. Angiogenesis, microvascular architecture, microhemodynamics, and interstitial fluid pressure during early growth of human adenocarcinoma LSI74T in SCID mice
32. Microvascular pressure is the principal driving force for interstitial hypertension in solid tumors: Implications for vascular collapse
33. Oxygen tension measurements of tumors growing in mice